Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 49Carcinoma, Renal Cell 30Neoplasm Metastasis 18Neoplasms 15Kidney Neoplasms 14Neuroendocrine Tumors 11Carcinoma, Neuroendocrine 9Prostatic Neoplasms 7Melanoma 7Triple Negative Breast Neoplasms 6Thyroid Neoplasms 6Sarcoma 6Meningioma 6Lymphoma 6Glioma 6Endometrial Neoplasms 6Tuberous Sclerosis 5Stomach Neoplasms 5Recurrence 5Lymphoma, Mantle-Cell 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Liver Neoplasms 4Carcinoma, Islet Cell 4Astrocytoma 4

Interventions

Filgrastim 3Cyclophosphamide 3sargramostim 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Irinotecan 2Etoposide 2Erlotinib Hydrochloride 2Cisplatin 2Carboplatin 2phenylacetic acid 1palbociclib 1olaparib 1erdafitinib 1becatecarin 1aldesleukin 1X-Rays 1Vinorelbine 1Topotecan 1Thiotepa 1Tamoxifen 1Sunitinib 1Specimen Handling 1Radiotherapy 1RMP 7 1Phantoms, Imaging 1Paclitaxel 1Nuclear Medicine Department, Hospital 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Familial ependymoma × Everolimus × Clear all
NCT02155920 2024-05-08

Everolimus for Children With Recurrent or Progressive Ependymoma

University of Texas Southwestern Medical Center

Phase 2 Completed
11 enrolled 13 charts

Familial ependymoma, Ependymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡